- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06866743
How Seasons Affect Kidney Health in Post-Menopausal Females
September 30, 2025 updated by: Joseph Watso, Florida State University
Seasonal Changes in Kidney Function Among Female Adults Post-Menopause
The investigators are assessing how seasonal changes affect kidney function biomarkers in post-menopausal women, an understudied group.
While heat stress can reduce kidney function, previous research has not accounted for physical activity, diet, hydration, or sun exposure.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Intense heat stress on the body can reduce kidney function.
A recent study reported that blood markers of kidney function are lower among people in hotter climates.
However, these data did not consider physical activity, food intake, fluid intake, time spent outdoors, or exposure to sunlight.
Therefore, the investigators invite participants to help determine whether there are seasonal changes in kidney function biomarkers.
This will also help the investigators understand if physical activity, food intake, fluid intake, time spent outdoors, or exposure to sunlight affect kidney function biomarkers between seasons.
The investigators are studying female adults post-menopause since they are an understudied group.
Study Type
Observational
Enrollment (Actual)
18
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Tallahassee, Florida, United States, 32306
- Florida State University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Participants will be recruited from the greater Tallahassee, Florida area.
Description
Inclusion Criteria:
- Female aged ≥55 years old
- Self Reported as at least one year post-menopause
- Live in Tallahassee, Florida, or the surrounding area
Exclusion Criteria:
- Have a BMI of ≥30 kg/m2
- Systolic blood pressure of ≥140 and/or diastolic blood pressure ≥90 mmHg
- Self Reported Current or recent (regular use within the past six months) use of a diuretic medication
- Self Reported: Uncontrolled cardiovascular, respiratory, neurological, renal, liver, or metabolic health condition
- Current or recent (regular use within the past six months) use of tobacco, nicotine, nonsteroidal anti-inflammatory products
- No regular (≥once per week) purposeful heat exposure (e.g., sauna, spa, etc.)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Winter
Assessment of the cohort in winter 2025 (visit 1).
|
This research focuses on examining seasonal variations in kidney function among postmenopausal females.
As an observational study, our approach is non-interventional.
|
|
Summer
Assessment of the cohort in summer 2025 (visit 2).
|
This research focuses on examining seasonal variations in kidney function among postmenopausal females.
As an observational study, our approach is non-interventional.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Plasma neutrophil gelatinase-associated lipocalin (NGAL)
Time Frame: Visit 1 (0 months) and Visit 2 (7 months)
|
Changes in NGAL will be measured in blood samples using enzyme-linked immunosorbent assay.
|
Visit 1 (0 months) and Visit 2 (7 months)
|
|
Urinary neutrophil gelatinase-associated lipocalin (NGAL)
Time Frame: Visit 1 (0 months) and Visit 2 (7 months)
|
Changes in NGAL will be measured in urine samples using radioimmunoassay.
|
Visit 1 (0 months) and Visit 2 (7 months)
|
|
Insulin-like growth factor-binding protein 7 (IGFBP7)*Tissue inhibitor of metalloproteinase-2 (TIMP-2)
Time Frame: Visit 1 (0 months) and Visit 2 (7 months)
|
The product of Insulin-like growth factor-binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinase-2 (TIMP-2) will be measured in blood samples using enzyme-linked immunosorbent assays.
|
Visit 1 (0 months) and Visit 2 (7 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
estimated glomerular filtration rate (eGFR)
Time Frame: Visit 1 (0 months) and Visit 2 (7 months)
|
eGFR will be calculated from creatinine using CKD-EPI equation.
|
Visit 1 (0 months) and Visit 2 (7 months)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Joseph Watso, PhD, Florida State University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 3, 2025
Primary Completion (Actual)
September 3, 2025
Study Completion (Actual)
September 3, 2025
Study Registration Dates
First Submitted
February 14, 2025
First Submitted That Met QC Criteria
March 4, 2025
First Posted (Actual)
March 10, 2025
Study Record Updates
Last Update Posted (Estimated)
October 6, 2025
Last Update Submitted That Met QC Criteria
September 30, 2025
Last Verified
September 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00005199
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Data with all HIPAA identifiers removed may be shared in future collaborative efforts pending appropriate data and/or material transfer agreement approvals.
IPD Sharing Time Frame
One year after completion of the trial, indefinitely
IPD Sharing Access Criteria
A formal plan identifying the intended use of the data and proper completion of appropriate data and/or material transfer agreement approvals with the study PI and their institution.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Female
-
Assiut UniversityNot yet recruitingFemale InfertilityEgypt
-
Nadezhda Women's Health HospitalRecruitingFemale Infertility | IVF PatientsBulgaria
-
Yuzuncu Yil UniversityCompletedUnexplained Infertility | Female Infertility | Anovulatory InfertilityTurkey (Türkiye)
-
Institute of Spa and Balneology, public research...Františkovy lázněNot yet recruitingRecurrent Pregnancy Loss | Female Infertility | Reproductive Disorders
-
Cairo UniversityCompleted
-
University Hospital, Clermont-FerrandCompletedInfertility | Infertility, FemaleFrance
-
Zagazig UniversityNot yet recruitingHemodynamic Instability | Infertility FemaleEgypt
-
University of Novi SadNot yet recruitingInfertility Female | Frozen Embryo Transfer (FET)Serbia
-
Shanghai 6th People's HospitalRecruiting
-
Alexandria UniversityCompleted
Clinical Trials on There will be no intervention.
-
University of Sao Paulo General HospitalRecruitingPulmonary Arterial Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension (PAH)Brazil
-
Bernardo Rodríguez IturbeCompletedHemodialysis | Arterial HypertensionMexico
-
University of OsloOslo University HospitalActive, not recruiting
-
Kutahya Health Sciences UniversityRecruitingDisease Management | Coronary Arterial Disease (CAD) | NURSİNG | LIFE SATISFACTIONTurkey (Türkiye)
-
Jagiellonian UniversityPiotr ChlostaCompletedTo Evaluate Lower Urinary Tract Symptoms (LUTS) in PolandPoland
-
Jagiellonian UniversityPiotr ChlostaUnknownTo Evaluate Lower Urinary Tract Symptoms (LUTS) and Their Impact on Quality of Life in Night WorkersPoland
-
Assuta Medical CenterUnknown
-
Imperial College LondonCompleted
-
Kuwait UniversityCompleted
-
Suleyman Demirel UniversityPamukkale UniversityCompleted